Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- The Rosen Law Firm PAROSEN, A LONGSTANDING FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPRWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineCapricor Therapeutics (CAPR) Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
- The Rosen Law Firm PAROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- Antengene Corporation LimitedAntengene Presents Key R&D Highlights at the Evercore 2nd China Biotech SummitAntengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- CARsgen TherapeuticsCARsgen Therapeutics Announces 2026 Interim ResultsCARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results. Business Highlights Cash and cash equivalents were around RMB1,400 million as of...
- Curavit Clinical ResearchCuravit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science SponsorsCombined operations deliver unified U.S. and European trial delivery, faster recruitment, and expanded evidence-generation capabilities across pharma, biotech, medtech, diagnostics, and digital health. BOSTON, Aug. 18, 2026 -- Curavit Clinical Research, an innovative clinical...
- Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine DevelopmentCompany says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built
- McConnell Law FirmCan Seeking Drug Treatment Help Your Criminal Case? | Drug Crimes Law Firm, WichitaIf you've been arrested on drug-related charges, you may be wondering whether entering a drug treatment program could help your case. It's a common question, especially for individuals whose charges are connected to substance use or addiction....
- Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor FitzgeraldChairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026
- Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD TreatmentFollows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program
- Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on August 17, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted an aggregate of 11,000 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
- Gemelli BiotechReal-World IBS Study Links IBS-Smart® and Trio-Smart® Testing to Lower Use of Selected Diagnostic Procedures and Lower Captured Diagnostic CostsST. LOUIS & DUBLIN, Ohio & MESA, Ariz., August 18, 2026--Gemelli Biotech today announced the publication of a real-world study in Frontiers in Gastroenterology evaluating healthcare resource utilization following IBS-Smart® and Trio-Smart® testing in adults with suspected irritable bowel syndrome (IBS). Gemelli Biotech funded the study and manufactures both tests.